Purpose: Despite all past efforts, the current guidelines are not explicit enough regarding the indications for performing azoospermia factor (AZF) screening and karyotype, burdening clinicians with the decision to assess whether such tests are meaningful for the infertile male patient. These assessments can be costly and it is up to the healthcare practitioner to decide which are necessary and to weigh the benefits against economic/psychological harm. The aim of this study is to address such gaps and provide update on current management options for this group of patients. Materials and Methods: To address such gaps in male infertility management and to elucidate whether AZF screening is indicated in individuals who concomitantly harbor chromosomal abnormalities we conducted a retrospective cohort analysis of 10,388 consecutive patients with non-obstructive azoospermia (NOA) and severe oligozoospermia. Results: Previously, it has been suggested that all NOA cases with chromosomal defects, except males with 46,XY/45,X karyotype, have no indication for AZF screening. Our findings revealed that cases carrying the following chromosomal abnormalities inv(Y)(p11.2q12); idic(Y)(q11.2); 46,XY,r(Y); idic(Y)(p11.2) and der(Y;Autosome) (76/169; 44.9%; 95% CI, 37.7–52.5) should also be referred for AZF deletion screening. Here, we also report the correlation between sperm count and AZF deletions as a secondary outcome. In accordance with previously reported data from North America and Europe, our data revealed that only 1% of cases with >1×106 sperm/mL had Y chromosome microdeletions (YCMs). Conclusions In the era of assisted reproduction, finding cost-minimization strategies in infertility clinics without affecting the quality of diagnosis is becoming one of the top prioritized topics for future research. From a diagnostic viewpoint, the results reflect a need to reconsider the different karyotype presentations and the sperm count thresholds in male infertility guidelines as indicators for YCM screening during an infertility evaluation.

Objective: To identify the anti-Toxoplasma antibodies from blood donors who referred to blood transfusion bases of Jahrom County, using ELISA method. Methods: Based on the prevalence and characteristics method, 400 serum samples were collected from blood donors referred to Jahrom blood transfusion bases, Southern Iran, during 2010-2011, designed at testing by ELISA. IgM and IgG antibodies against Toxoplasma gondii were tested using ELISA kits (Dia-Pro) on serums. The data were analysed by SPSS 19 software. Results: Review of 400 cases, 54 of them were IgG positive for parasites (13.5%) and 346 of those with negative IgG (86.5%). In IgM examination, 1.75% of them have been positive IgM (7 cases) and 98.25% of them were IgM negative (393 cases). By comparing the different group ages, 40-50 year age group had the highest prevalence of IgG positive (17.9%) and the age group of 30-40 years had the highest incidence of IgM negative (2.5%). Conclusions: Due to the serological infection rate of toxoplasmosis obtained from this study, toxoplasmosis should be considered as a significant transfusion risk factor in Jahrom and also in any region with similar situations.